Adalimumab for moderate to severe chronic plaque psoriasis: Efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

British Journal of Dermatology

Volumn 164, Issue 2, 2011, Pages 434-441

  Papp, Kim ^a   Crowley, J ^b   Ortonne, J P ^c   Leu, J ^d   Okun, M ^d   Gupta, S R ^d   Gu, Y ^d   Langley, R G ^e  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b Bakersfield Dermatology   (United States)

^c UNIVERSITY HOSPITAL OF NICE   (France)

^d ABBOTT LABORATORIES   (United States)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY;

ABDOMINAL ADHESION; ADULT; ALLERGIC REACTION; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEPATITIS C; HUMAN; HUMERUS FRACTURE; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; LONG TERM CARE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; NEPHROLITHIASIS; OPEN STUDY; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PHYSICIAN GLOBAL ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; REBOUND; RECURRENT DISEASE; RELAPSE; RETREATMENT; SCORING SYSTEM; SIDE EFFECT; SKIN CANCER; TENDON RUPTURE; THORAX PAIN; TISSUE ADHESION; TREATMENT WITHDRAWAL; UMBILICAL HERNIA;

ADULT; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RECURRENCE; RETREATMENT; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79551488770     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10139.x     Document Type: Article

References (14)

1. Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010; 162: 1349-58.
2. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
3. Saurat JH, Stingl G, Dubertret L, et al. CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66.
4. Gordon K, Blum R, Papp K, et al. Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized clinical trial. Psoriasis Forum 2007; 13: 4-11.
5. Gordon K, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomised controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
6. Fredriksson T, Pettersson U,. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
7. Ko H-S,. Clinical trial design in psoriasis. Oral presentation at: 49th Meeting of the Dermatologic and Ophthalmologic Advisory Committee, 20 March 1998, Bethesda, MD.
8. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63-74.
9. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700-21.
10. Webster K, Cella D, Yost K,. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1: 79.
11. Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002; 24: 547-61.
12. Lebwohl M, Blum R, Gordon K, Okun M,. Efficacy and safety of a second adalimumab treatment cycle in psoriasis patients who relapsed after adalimumab discontinuation or dosage reduction. Poster presentation P201 at the 18th Congress of the European Academy of Dermatology and Venereology, 7-11 October 2009, Berlin, Germany.
13. Menter A, Gu Y, Sasso E,. Relationship between effectiveness of restarting adalimumab and degree of psoriasis activity after a period of discontinuation. J Am Acad Dermatol 2009; 60 (Suppl.): AB183.
14. Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127-32.